APPROXIMATELY one year ago, a paper1 was published describing 57 tuberculous patients with otolaryngeal complications treated at the Fitzsimons General Hospital with streptomycin. Studies had been made with these patients since July 1946, when Fitzsimons General Hospital became a participating hospital in the federal services joint program of streptomycin research. The cases studied during the past year do not differ materially in qualitative results of therapy from those studied during the latter part of the previous period, but they do add quantitative support to the striking results experienced with this new therapeutic agent.
A detailed analysis of these cases will not be given, since it is generally well known that low dosages of streptomycin are just as efficacious as the originally used high dosages and that administration through the intramuscular route is preferable to local therapy for otolaryngeal lesions. There now appear to be prospects of several new methods